Age due | Diseases protected against | Vaccine given | Trade name | Usual site |
8 weeks | Diphtheria, tetanus, pertussis (whooping cough), polio, Haemophilus influenzae type b (Hib) and hepatitis B | DTaP/IPV/Hib/HepB (6-in-1) | Infanrix hexa or Vaxelis | Thigh |
Meningococcal group B (MenB) | MenB | Bexsero | Left thigh | |
Rotavirus gastroenteritis | Rotavirus | Rotarix | By mouth | |
12 weeks | Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B | DTaP/IPV/Hib/HepB (6-in-1) | Infanrix hexa or Vaxelis | Thigh |
Pneumococcal (13 serotypes) | PCV | Prevenar 13 | Thigh | |
Rotavirus gastroenteritis | Rotavirus | Rotarix | By mouth | |
16 weeks | Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B | DTaP/IPV/Hib/HepB (6-in-1) | Infanrix hexa or Vaxelis | Thigh |
Meningococcal group B (MenB) | MenB | Bexsero | Left thigh | |
1 year | Hib and MenC | Hib/MenC | Menitorix | Upper arm/thigh |
Pneumococcal (13 serotypes) | PCV booster | Prevenar 13 | Upper arm/thigh | |
Measles, mumps and rubella | MMR | MMRvaxPro or Priorix | Upper arm/thigh |
The Black Triangle Scheme ▾
Continued monitoring of medicines by The Commission on Human Medicines (CHM) and the The Medicines and Healthcare products Regulatory Agency (MHRA). To read more about drug safety monitoring please visit MHRA website here.
Flu vaccines
Flu vaccines available for the 2024 to 2025 season
Licensed from age | Vaccine | Manufacturer |
6 months | Quadrivalent Influenza Vaccine, egg-grown (QIVe) | Sanofi |
6 months | Influenza Tetra MYL, Quadrivalent Influenza Vaccine, egg-grown (QIVe) | Viatris (formerly Mylan) |
6 months | ▾ Cell-based Quadrivalent Influenza Vaccine, egg free (QIVc) | CSL Seqirus |
2 years to less than 18 years of age | Fluenz, live attenuated influenza vaccine (LAIV) | AstraZeneca |
60 years | ▾ Quadrivalent Influenza Vaccine – High Dose, egg grown (QIV-HD) | Sanofi |
65 years | ▾ Adjuvanted Quadrivalent Influenza Vaccine (aQIV) | Seqirus |
The Black Triangle Scheme ▾
Continued monitoring of medicines by The Commission on Human Medicines (CHM) and the The Medicines and Healthcare products Regulatory Agency (MHRA). To read more about drug safety monitoring please visit MHRA website here.
Covid-19
SARS-CoV-2 Messenger RNA (mRNA) vaccines available for the 2024 to 2025 season
▾ Comirnaty (Pfizer-BioNTech)
▾ Spikevax (Moderna)
The Black Triangle Scheme ▾
Continued monitoring of medicines by The Commission on Human Medicines (CHM) and the The Medicines and Healthcare products Regulatory Agency (MHRA). To read more about drug safety monitoring please visit MHRA website here.